Skip to main content
. 2021 Dec 3;13(23):6092. doi: 10.3390/cancers13236092

Figure 1.

Figure 1

Somatic mutations detected in the sample cohort. (A) An integrated analysis of the sample cohort (66 samples) depicts the top tier 1 mutations. The samples are grouped by recurrence status, IDH mutation status, presence of mutational signature 11, and TMB phenotype. Complete information of all genetic alterations can be found in the database (https://clinomics.ccr.cancer.gov/clinomics/public/login accessed date: 20 November 2021) (B) High confidence somatic variants count analysis shows that tier 1 high confident somatic mutations contain a higher percentage of expressed mutations than the total high confident somatic mutations. (C) Matched recurrent glioma samples share expressed somatic mutations. Total number of expressed somatic mutations is labeled for each patient. Patients labeled in red carry HMP tumors, and patients labeled in black carry NHMP tumors. NHMP, TMB less than 10 mutations per Mb. HMP, TMB more than 10 mutations per Mb. ND, newly diagnosed tumor. R, recurrent tumor.